Active opportunistic infections and/or low CD4+T-cell (CD4+) counts are exclusion criteria in most clinical trials. Late presenters (LP) are therefore inadequately represented in studies comparing efficacy of antiretroviral regimens, leading to a lack of data on optimal treatment options. Our study aimed to investigate the efficacy and safety of first line ART with integrase-inhibitor (INSTI) or protease-inhibitor (PI) based regimens in patients with low CD4+ counts and/or an AIDS-defining disease.
We conducted a retrospective, multicenter analysis to investigate discontinuation rates and clinical outcome in patients with a CD4 cell count <200/µL and/or an AIDS defining disease after starting first line ART. Data were collected in three European HIV clinics: Universityhospital Frankfurt, Kings College London and Hospital Fundación Jiménez Díaz Madrid. All patients with CD4<200/µL and/or an AIDS defining disease who started INSTI or PI-based first line ART between January 2014 and December 2016 were included in this study. Proportions of those discontinuing ART and with adverse events were compared using univariate analysis. Virologic response was analyzed by using FDA snapshot analysis (HIV-1 RNA <50 copies/mL at week 48).
A total of 218 LP were included in the study, 13.8% women, 23.8% non-European ethnicity with a mean (SD) baseline CD4 91/µL (112) and CD4/CD8 ratio of 0.11 (0.19). 131 LP were started on INSTI-based regimen and 87 on PI`s. Between-group differences are presented in table 1. Those commenced on PI were more likely to be older; 91.8% of the INSTI and 92.4% of PI treated patients had a viral load <50 copies/mL at week 48, discontinuation rates due to adverse events were 3.4% in the INSTI and 8.1% in the PI group respectively. No significant differences in discontinuation rates were observed at week 12 or 48 between INSTI and PI-based regimens (p=0.78 and 0.47 respectively). Virologic response was equally good in those receiving integrase or protease inhibitors (91.8% vs. 92.4%; p = 0.88; odds ratio (95% CI) 1.05 (0.38– 2.82).
In a European cohort of LP starting first line INSTI or PI based ART regimens, there were no significant differences in discontinuation rates or virologic response at week 48. Our results indicate that the choice between INSTI and PI can be made on an individual basis of the patient presenting late for first line ART. Future research will focus on the identifying factors associated with regimen selection in this cohort.